Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

Just because they presented data on the original unblinded 19 patients for B-OM, does not mean more patients have not been added. Due to the blinding process, data can not be analyzed on a rolling basis.

Regardless, the highly encouraging previously released B-OM data, in addition to the newly released B-UP date, make a very compelling story regarding its anti-inflammatory as well as previously known antibiotic properties.

I expect after today's news, IPIX will be meeting with many of the large pharma companies over the next 1 to 6 months, and will evaluate the best deal to increase shareholder value.

This is an exciting time and the best is yet to come!